首頁 > 市場調查報告書 > 醫療設備

糖尿病

市場調查報告書

商品編碼

1898206

糖尿病護理設備和藥品市場規模、佔有率和成長分析（按類型、通路、最終用途和地區分類）—2026-2033年行業預測

Diabetes Care Devices and Drugs Market Size, Share, and Growth Analysis, By Type (BGM Devices, Insulin Delivery Devices), By Distribution Channel (Hospital pharmacies, Retail Pharmacies), By End-use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，糖尿病護理設備和藥品市場規模將達到 325.6 億美元，到 2025 年將達到 351.3 億美元，到 2033 年將達到 645.5 億美元，預測期（2026-2033 年）的複合年成長率為 7.9%。

糖尿病的特徵是由於胰島素分泌不足導致的高血糖症，仍然是全球面臨的重大健康挑戰。持續血糖監測設備在糖尿病管理中發揮著至關重要的作用，使患者能夠輕鬆追蹤全天的血糖值。糖尿病影響全球數百萬人口，並帶來許多重大風險，包括腎衰竭和心血管事件等併發症。由於肥胖率上升、久坐不動的生活方式以及大眾對糖尿病的認知不足，中低收入國家的糖尿病盛行率尤其高。預計1型和2型糖尿病新診斷患者數量的持續成長將維持對糖尿病照護設備的需求。胰島素輸注系統的日益普及以及製造商為拓展治療方案和改善糖尿病管理患者預後而不斷進行的創新努力，進一步推動了這一需求。

糖尿病護理設備和藥品市場成長要素

糖尿病照護設備和藥品市場的成長主要受到旨在改善糖尿病管理的創新產品不斷湧現的顯著影響。糖尿病監測系統和治療設備的進步推動了這一市場擴張，例如，目前正在進行的研究探索了諸如含胰島素奈米顆粒塗層等增強口服胰島素遞送的方法。此外，研發投入的增加以及各相關人員之間的合作預計將進一步推動市場成長。這種充滿活力的環境鼓勵開發先進解決方案，最終改善患者預後並推動市場需求。

糖尿病照護設備和藥品市場面臨的限制

糖尿病照護設備和藥品市場的成長可能受到多種因素的阻礙，例如某些地區報銷政策不完善和監管嚴格。此外，與糖尿病密切相關的肥胖症日益增多，也對市場擴張構成挑戰。同時，尤其是在開發中國家，人們對糖尿病診斷和治療方案的認知嚴重不足，進一步阻礙了市場的潛在發展。這些問題疊加在一起，構成了阻礙全球糖尿病照護解決方案整體進步和發展的重大障礙。

糖尿病護理設備和藥品市場趨勢

糖尿病照護設備和藥品市場正處於積極的成長軌道上，這主要得益於人們對糖尿病管理的認知和關注度不斷提高，尤其是在新冠疫情等健康挑戰的背景下。糖尿病患者被認為感染風險更高，這顯著增加了對監測設備和居家治療方案的需求。這一趨勢反映出人們對遠端醫療解決方案的日益青睞，從而提升了患者的自主性和治療依從性。此外，個人化醫療領域的技術創新和進步也持續推動著市場發展，塑造出一個充滿活力且不斷演變的市場格局，其核心在於改善病患的治療效果和生活品質。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Novo Nordisk（Denmark）
Medtronic（Ireland）
Abbott Laboratories（United States）
Johnson & Johnson（United States）
Biocon（India）
Eli Lilly and Company（United States）
Roche（Switzerland）
Bayer（Germany）
Dexcom（United States）
Insulet Corporation（United States）
Tandem Diabetes Care（United States）
Ascensia Diabetes Care（Switzerland）
Terumo Corporation（Japan）
Becton, Dickinson and Company（United States）
AstraZeneca（United Kingdom）
Pfizer（United States）
Merck & Co.（United States）
GlaxoSmithKline（United Kingdom）
McKesson Corporation（United States）

結論與建議

簡介目錄

Product Code: SQMIG35G2119

Diabetes Care Devices and Drugs Market size was valued at USD 32.56 Billion in 2024 and is poised to grow from USD 35.13 Billion in 2025 to USD 64.55 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

Diabetes remains a critical global health challenge, characterized by inadequate insulin production leading to elevated blood glucose levels. Continuous glucose monitors, pivotal in diabetes management, enable patients to track their glucose levels effortlessly throughout the day. With millions affected worldwide, diabetes poses significant risks, including complications such as kidney failure and cardiovascular events. The prevalence is particularly prominent in low- and middle-income nations, attributed to rising obesity rates, sedentary lifestyles, and limited awareness. The upward trend in newly diagnosed type 1 and type 2 diabetes cases is projected to sustain demand for diabetes care devices. This demand is further fueled by the increasing adoption of insulin delivery systems and manufacturers' commitment to innovation, enhancing treatment options and improving patient outcomes in diabetes management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetes Care Devices and Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetes Care Devices and Drugs Market Segments Analysis

Global Diabetes Care Devices and Drugs Market is segmented by Type, Distribution Channel, End-use and region. Based on Type, the market is segmented into BGM Devices and Insulin Delivery Devices. Based on Distribution Channel, the market is segmented into Hospital pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies and Others. Based on End-use, the market is segmented into Hospitals, Diagnostic Centers and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetes Care Devices and Drugs Market

The growth of the diabetes care devices and drugs market is significantly influenced by the continuous introduction of innovative products aimed at improving diabetes management. Advancements in diabetes monitoring systems and treatment devices contribute to this expansion, as evidenced by ongoing research initiatives exploring methods like coating insulin-loaded nanoparticles to enhance oral insulin delivery. Furthermore, heightened investments in research and development, alongside collaborative efforts among various stakeholders, are expected to foster additional opportunities for market growth. This dynamic environment encourages the creation of advanced solutions, ultimately improving patient outcomes and driving market demand.

Restraints in the Diabetes Care Devices and Drugs Market

The growth of the diabetes care devices and drugs market may be hindered by various factors, including inadequate reimbursement policies and strict regulations in certain regions. Additionally, the increasing prevalence of obesity, which is closely linked to diabetes, poses challenges for market expansion. Moreover, a significant lack of awareness regarding diabetes diagnosis and treatment options, particularly in developing countries, further obstructs the potential advancement of this market. These combined issues create substantial obstacles that could impede the overall progress and development of diabetes care solutions across the globe.

Market Trends of the Diabetes Care Devices and Drugs Market

The Diabetes Care Devices and Drugs market is experiencing a positive trajectory driven by heightened awareness and concern about managing diabetes, particularly in the context of health challenges like the coronavirus. As individuals with diabetes are recognized as being at increased risk, there has been a substantial surge in demand for monitoring devices and therapeutic solutions that facilitate at-home management. This trend reflects a growing preference for remote healthcare solutions, enhancing patient autonomy and adherence to treatment regimens. Additionally, innovations in technology and personalized medicine continue to fuel advancements, creating a dynamic and evolving market landscape focused on improved patient outcomes and quality of life.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Diabetes Care Devices and Drugs Market Size by Type & CAGR (2026-2033)

Market Overview
BGM Devices
- Self-Monitoring Devices
- Blood Glucose Meters
- Testing Strips
- Lancets
- Continuous Glucose Monitoring Devices
- Sensors
- Transmitters
- Receiver
Insulin Delivery Devices
- Pumps
- Pens
- Syringes and Needles
- Jet Injectors

Global Diabetes Care Devices and Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital pharmacies
Retail Pharmacies
Diabetes Clinics/Centers
Online Pharmacies
Others

Global Diabetes Care Devices and Drugs Market Size by End-use & CAGR (2026-2033)

Market Overview
Hospitals
Diagnostic Centers
Homecare

Global Diabetes Care Devices and Drugs Market Size & CAGR (2026-2033)

North America (Type, Distribution Channel, End-use)
- US
- Canada
Europe (Type, Distribution Channel, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Distribution Channel, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Distribution Channel, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Distribution Channel, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dexcom (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insulet Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tandem Diabetes Care (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ascensia Diabetes Care (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
McKesson Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments